It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Resumo
Proton therapy as a promising candidate in cancer treatment has attracted much attentions and many studies have been performed to investigate the new methods to enhance its radiation effectiveness. In this regard, two research groups have suggested that using boron isotopes will lead to a radiation effectiveness enhancement, using boron-11 agent to initiate the proton fusion reaction (P-BFT) and using boron-10 agent to capture the low energy secondary neutrons (NCEPT). Since, these two innovative methods have not been approved clinically, they have been recalculated in this report, discussed and compared between them and also with the traditional proton therapy to evaluate their impacts before the experimental investigations. The calculations in the present study were performed by Geant4 and MCNPX Monte Carlo Simulation Codes were utilized for obtaining more precision in our evaluations of these methods impacts. Despite small deviations in the results from the two MC tools for the NCEPT method, a good agreement was observed regarding the delivered dose rate to the tumor site at different depths while, for P-BFT related calculations, the GEANT4 was in agreement with the analytical calculations by means of the detailed cross-sections of proton-11B fusion. Accordingly, both the methods generate excess dose rate to the tumor several orders of magnitude lower than the proton dose rate. Also, it was found that, the P-BFT has more significant enhancement of effectiveness, when compared to the NCEPT, a method with impact strongly depended on the tumor’s depth. On the other hand, the advantage of neutron risk reduction proposed by NCEPT was found to give no considerable changes in the neutron dose absorption by healthy tissues.
Você solicitou a tradução automática realizada por máquina do conteúdo selecionado de nossas bases de dados. Essa funcionalidade é oferecida apenas para sua conveniência e não pretende, de maneira nenhuma, substituir a tradução humana. Mostrar a renúncia completa
A ProQuest ou seus licenciadores não fazem representações ou garantias a respeito das traduções. As traduções são geradas automaticamente "NO ESTADO EM QUE SE ENCONTRAM" e "CONFORME DISPONÍVEL" e não são mantidas em nossos sistemas. A PROQUEST E SEUS LICENCIADORES ESPECIFICAMENTE RENUNCIAM A TODAS AS GARANTIAS, EXPRESSAS OU IMPLÍCITAS, INCLUINDO, SEM LIMITAÇÃO QUALQUER GARANTIA DE DISPONIBILIDADE, PRECISÃO, PONTUALIDADE, INTEGRIDADE, NÃO INFRINGIMENTO, COMERCIABILIDADE OU ADEQUABILIDADE A UMA FINALIDADE ESPECÍFICA. O uso das traduções está sujeito a todas as restrições de uso contidas em seu Acordo de Licença de Produtos Eletrônicos e ao usar a funcionalidade de tradução, você concorda em abdicar de toda e qualquer reclamação contra a ProQuest ou seus licenciadores pelo uso da funcionalidade de tradução e qualquer resultado derivado dela. Ocultar a renúncia completa
Detalhes
1 Nuclear Science and Technology Research Institute, Tehran, Iran (GRID:grid.459846.2) (ISNI:0000 0004 0611 7306)
2 Northern Illinois University, Department of Chemistry and Biochemistry, DeKalb, USA (GRID:grid.261128.e) (ISNI:0000 0000 9003 8934)